(PRGO) Perrigo Company plc BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PRGO) Perrigo Company plc Complete Analysis Pack
Unlock Strategic Clarity
This Perrigo Company plc BCG Matrix helps you quickly assess how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio planning. The page already shows a real preview of the analysis, so you can review the actual content and format before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Opill, 1st OTC daily oral contraceptive in the US
Opill, launched in 2023, is Perrigo Company plc’s clearest Star: the first OTC daily oral contraceptive in the U.S. and a new women’s health category it helped create. First-mover status, broad retail reach, and rising brand awareness support its growth. Perrigo said Opill posted strong momentum in 2025, and that scale keeps it in the Star box.
Compeed, blister care across 23 countries
Compeed is sold in 23 countries and is one of Perrigo Company plc’s strongest international self-care brands. Its broad European reach and blister-care category support repeat purchases and premium pricing. If Compeed keeps growing faster than the market, it can stay a Star in Perrigo Company plc’s BCG Matrix.
Private-label vitamins, minerals and supplements
Private-label vitamins, minerals and supplements are a Star for Perrigo Company plc because demand is recurring and tied to everyday wellness. Perrigo’s store-brand scale across North America supports shelf presence, pricing power, and steady volume in a category that benefits from preventive health spending. In FY2025, this looks attractive because consumer health remains a core, repeat-purchase market rather than a one-time buy.
Plackers REACH Steripod oral-care brands
Plackers, REACH, and Steripod fit a Star view because oral hygiene is a large self-care category, and Perrigo’s U.S. retail reach helps keep shelf space and repeat buys. Perrigo reported about $4.4 billion in fiscal 2025 net sales, so these brands sit inside a scale player with room to defend share. If category growth stays strong, their mix can keep producing high-velocity retail sales.
- Large, repeat-buy oral care segment
- Strong retail shelf access
- Supports Star growth profile
Consumer Self-Care International growth brands
Perrigo Company plc's Consumer Self-Care International growth brands operate in about 23 countries and sell through pharmacies, wholesalers, and drugstores. The branded OTC portfolio is growing faster than many mature U.S. categories, so it fits the Star profile in the BCG matrix.
Europe expansion can keep volume and mix improving, which supports higher-return growth if share gains hold.
- About 23-country reach
- OTC brands outgrow mature U.S. categories
- Europe can extend Star-like returns
Perrigo’s growth stars: Opill, Compeed, and private-label wellness
Stars in Perrigo Company plc are Opill, Compeed, and select private-label vitamins, minerals and supplements. In FY2025, Perrigo reported about $4.4 billion in net sales, and Opill kept scaling as the first U.S. OTC daily oral contraceptive. Compeed reaches 23 countries, while store-brand wellness stays a repeat-buy engine.
| Star asset | FY2025 support |
|---|---|
| Opill | First U.S. OTC daily pill |
| Compeed | 23-country reach |
| VMS private label | Repeat demand |
What is included in the product
Detailed Word Document
Perrigo’s BCG Matrix maps its OTC and self-care brands to guide invest, hold, or divest decisions.
Editable Excel File
Perrigo Company plc BCG Matrix, at-a-glance quadrant view to simplify portfolio decisions and reduce analysis overload
Reference Sources
Provides a clear source trail for Perrigo Company plc, boosting credibility and helping decision-makers verify key assumptions fast.
Cash Cows
Private-label pain relief
Private-label pain relief is a classic cash cow for Perrigo Company plc: OTC pain products sell on repeat, and store-brand scale keeps shelves full with low unit costs. In Perrigo Company plc's FY2025 base, net sales were about $4.4 billion, with this low-growth, high-share category helping fund cash flow and margins.
Private-label digestive health
Private-label digestive health fits Cash Cows because it is a mature, repeat-buy category, not one that needs heavy R&D. Perrigo Company plc’s broad retail reach helps it move these products at scale, supporting cash generation from FY2025 net sales of about $4.4 billion. With stable demand and limited innovation spend, the business can keep producing cash while requiring only modest reinvestment.
Private-label upper respiratory remedies
Cold, cough and congestion remedies are mature consumer staples, so Perrigo Company plc can lean on private-label scale to protect share without big growth spend. In a cash-cow setup, the category helps fund the rest of the portfolio; Perrigo’s 2024 net sales were about $4.4 billion, and these stable OTC lines typically convert demand into cash rather than heavy capex.
Prevacid 24HR, established OTC acid reducer
Prevacid 24HR is a mature OTC lansoprazole 15 mg brand with a built-in repeat user base, and that fits a Cash Cow profile in Perrigo Company plc's BCG Matrix. Acid reducers sit in a low-growth category, but the 14-day therapy and strong shelf presence can still support steady cash flow and margin.
- Mature OTC franchise
- Low-growth category
- Repeat, need-based demand
- Cash flow support
Its value is not growth; it is dependable sales from an established consumer base. That makes Prevacid 24HR a steady contributor when Perrigo needs earnings stability.
Good Sense store-brand OTC
Good Sense is Perrigo Company plc’s broad store-brand OTC platform, covering everyday self-care needs like pain relief, allergy, cough, and digestive care. Its low-price, private-label model supports steady repeat buying in mature U.S. OTC categories, which keeps volume high even when growth is limited. That mix fits a Cash Cow: stable turnover, modest capital needs, and reliable cash generation.
- Broad private-label OTC reach
- Fits mature, low-growth categories
- Supports steady cash flow
- Low-price value drives repeat demand
Perrigo’s Cash Cows: Repeat OTC Sales Power Stable Cash Flow
Perrigo Company plc’s Cash Cows are mature private-label OTC lines—pain, digestive, cough/cold, and Prevacid 24HR—that sell on repeat and need little reinvestment. In FY2025, Perrigo Company plc reported about $4.4 billion in net sales, so these low-growth brands help fund cash flow and margins. Good Sense also fits, because broad store-brand reach keeps volume steady.
| Cash Cow | Why it fits | FY2025 cue |
|---|---|---|
| Private-label OTC | Repeat demand | $4.4B net sales |
Get Your Copy
Perrigo Company plc Reference Sources
The Perrigo Company plc BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo version, no missing sections—just the full, ready-to-use report. It’s formatted for clear strategic analysis and immediate download. What you preview is what you get.
Dogs
Rembrandt whitening
Rembrandt whitening sits in a crowded, promo-heavy teeth-whitening market where shelf space and ad spend drive sales. Perrigo’s brand does not match the scale of its core private-label lines, so it lacks the share needed to win consistently. With low share and slower category growth, it fits the Dog bucket in a BCG Matrix.
Firefly kids oral care
Firefly kids oral care fits Dog territory in Perrigo Company plc's BCG Matrix. It is a niche children's brand in a crowded oral-care market, with far less scale than Perrigo's stronger OTC franchises. Its small share and limited growth make it a weak cash user, not a clear growth engine.
Contract manufacturing services
Contract manufacturing services sit outside Perrigo Company plc’s core branded self-care model, so they usually add less strategic value than products the Company owns and markets itself. This work is often lower margin and more price-competitive, and if volume is small it fits the BCG "Dog" profile. Perrigo Company plc’s latest public filings should be checked for segment revenue and margin, because the cash return here depends heavily on scale.
Legacy low-share OTC brands
Legacy low-share OTC brands sit in the Dogs box because they have weak shelf pull and little pricing power. In Perrigo Company plc, small brands that do not meaningfully move revenue can still absorb working capital, trade spend, and store support. One line: low share plus slow growth usually means low return on capital.
- Weak shelf momentum
- Small revenue contribution
- Capital tied up
- Low return potential
For Perrigo Company plc, these brands are best judged by cash drain, not history. If a label cannot win repeat sales or defend distribution, it can stay a drag on margin and management time.
Non-core licensed consumer brands
Perrigo Company plc's non-core licensed consumer brands sit outside its store-brand OTC engine, so they are harder to scale and usually face sharper competition and thinner margins. That profile fits the Dog quadrant: low share, weak economics, and limited strategic fit.
- Lower fit with Perrigo's OTC core
- Harder to grow at scale
- More competition, weaker returns
These brands can still generate cash, but they are not the main growth driver.
Perrigo’s Dog Brands: Low Share, Thin Margins, Little Growth
Perrigo Company plc’s Dogs are small, low-share lines that tie up cash but do not scale. Rembrandt whitening, Firefly kids oral care, and other legacy OTC or licensed brands face weak shelf pull, heavy promo spend, and thin margins. They are better viewed as cash users than growth drivers.
| Dog area | Why it fits | BCG signal |
|---|---|---|
| Rembrandt | Low share, promo-heavy | Dog |
| Firefly | Niche, limited scale | Dog |
| Legacy OTC / licensed | Weak fit, thin returns | Dog |
Question Marks
ScarAway scar treatment
ScarAway sits in a skin care market that keeps growing, but scar treatment is still a niche OTC segment. Perrigo’s 2025 net sales were about $4.4 billion, yet ScarAway needs much higher share to turn brand awareness into real category power. That profile fits a Question Mark: known name, but not enough scale to win.
Zephrex D decongestant
Zephrex D is a small cold-and-flu decongestant brand in Perrigo Company plc’s OTC mix, so it fits the Question Mark slot. Demand can grow, but shelf space is still thin versus Perrigo’s larger brands, and the brand must win against crowded retail rivals. It needs more spend and store support to prove it can scale.
Opill international rollout
Opill fits Question Mark territory: its U.S. OTC launch is still the main revenue engine, while non-U.S. rollout is early and uneven. Perrigo still has to win country-by-country approvals, labels, and awareness in women’s health markets that are large but tightly regulated. That makes the opportunity real, but the execution risk high until international sales scale.
Burt’s Bees natural-care expansion
Burt’s Bees fits the Question Marks box: natural personal care keeps growing, but Perrigo has not yet turned that demand into dominant shelf space or brand pull. The bet is clear: if Perrigo can win more retail facings and keep Burt’s Bees top-of-mind, the brand can scale; if not, growth may stay uneven.
- Shelf space is the main gatekeeper
- Brand pull still needs more lift
- Growth exists, share is not dominant
E-commerce brand expansion
Perrigo Company plc’s e-commerce brand expansion looks like a Question Mark: online self-care keeps growing faster than many store channels, but Perrigo’s direct digital share is still limited. In 2024, Perrigo reported net sales of about $4.4 billion, so even small online gains can move the needle. The channel is attractive, but it is still a low-share bet for now.
- Online demand is rising faster than store sales.
- Perrigo still has room to gain share.
- Digital expansion needs selective brand investment.
Perrigo’s Question Marks: Growth Upside, But Scale Still Lags
Question Marks in Perrigo Company plc’s BCG Matrix are brands with growth upside but weak scale today. In fiscal 2025, Perrigo Company plc had about $4.4 billion in net sales, yet brands like ScarAway, Zephrex D, Opill, and Burt’s Bees still need more share, shelf space, or market approvals to turn demand into profit. They can grow, but each still needs heavier investment to win.
| Question Mark | 2025 signal | BCG view |
|---|---|---|
| ScarAway | Niche OTC scar care | Growth, low share |
| Zephrex D | Small cold brand | Needs scale |
| Opill | Early global rollout | High upside, high risk |
| Burt’s Bees | Natural care demand | Share still thin |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.